API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Historical End-of-Day API Real-time Prices API Financial Events & News API Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 152 articles Forum Github 14 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. F /
  3. 30J.F

IDEAYA BIOSCIENCE DL-01 (30J F) stock market data APIs

€27.6 0(0%) as of October 29, 2024
Price chart is built with Anychart

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

IDEAYA BIOSCIENCE DL-01 Financial Data Overview

27.6
27.6
-
27.6
27.6
26.4-44.4
2 360 M
84 482 K
11 961 K
-0.33
0.816
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '30J',
Type: 'Common Stock',
Name: 'IDEAYA BIOSCIENCE DL-01',
Exchange: 'F',
CurrencyCode: 'EUR',
CurrencyName: 'Euro',
CurrencySymbol: '€',
CountryName: 'Germany',
CountryISO: 'DE',
OpenFigi: NULL,
ISIN: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
CUSIP: NULL,
}

IDEAYA BIOSCIENCE DL-01 Fundamental Data is available in our Financial Data APIs

  • Net Revenue 11 961 K
  • EBITDA -188 878 000
  • Earnings Per Share -2.02
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get IDEAYA BIOSCIENCE DL-01 Earnings via APIs

  • Latest Release 2021-06-30
  • EPS/Forecast -0.1

Get IDEAYA BIOSCIENCE DL-01 End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get IDEAYA BIOSCIENCE DL-01 latest news via APIs

IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium

SOUTH SAN FRANCISCO, Calif., Oct. 4, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeut...

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap...
News API is available at any package from $19.99 See full price
Get sample of News API
Do you have any questions?
support@eodhistoricaldata.com